Response Biomedical To Present Two International Studies At Tenth Congress of Chest Pain Centers



    VANCOUVER, April 25 /CNW/ - Response Biomedical Corporation (TSX-V: RBM,
OTCBB: RPBIF) today announced that it is presenting data from two
international studies at the Tenth Congress of Chest Pain Centers - The Chest
Pain Center - A Team Approach in ACS Care, April 25-28, 2007 in Nashville, TN.
The studies, conducted in France and Italy, both concluded that the RAMP(R)
NT-proBNP assays evaluated performed equivalently to the local laboratory
systems.
    "Clinical Utility of the RAMP Whole Blood NT-proBNP Assay for the
Exclusion of Acute Heart Failure" showcases data from a clinical trial
conducted at the Laboratoire de Biochimie Générale et Spécialsée, Hôpital
Civil, Strabourg, France. The aim of the study was to compare the RAMP
point-of-care (POC) and laboratory based Dade Dimension RxL systems for
measurement of NT-proBNP levels in patients suspected of having heart failure
(HF). Clinical concordance analysis showed excellent clinical agreement
between the RAMP and the Dimension RxL. The RAMP NT-proBNP whole blood assay
was shown to be an accurate indicator that can be used to rule out acute HF in
the trial's patient population, with results comparable to the Dimension RxL,
laboratory analyzer. With results available in 15 minutes, the RAMP NT-proBNP
Assay allows for rapid initiation of appropriate patient treatment.
    "Evaluation of RAMP Whole Blood Analyzer for POC Troponin I (TnI) and
NT-proBNP Testing" outlines data from a clinical trial conducted at the
Laboratorio di Chimica Clinica ed Ematologia, Ospedale S. Bortolo, Vicenza,
Italy. The study evaluated the performance of the RAMP POC whole blood tests
for TnI and NT-proBNP for the accurate and rapid measurement of bio-markers to
aid in the diagnosis of cardiovascular disease. Both RAMP assays showed strong
correlation with the respective laboratory assays (NT-proBNP R=0.945 and 0.981
for TnI and NT-proBNP respectively). Clinical concordance between the RAMP POC
and the laboratory systems was 87% for TnI and 97.6% for NT-proBNP. The
posters will be available on our Web site at www.responsebio.com later today.

    About the Tenth Congress of Chest Pain Centers
    The Congress is the premier educational forum for coronary healthcare
professionals in the developing discipline of chest pain management.

    About Response Biomedical
    Response Biomedical develops, manufactures and markets rapid on-site
diagnostic tests for use with its portable RAMP Platform for clinical and
environmental applications. RAMP represents a new paradigm in diagnostics that
provides high sensitivity and reliable information in minutes. It is ideally
suited to both point-of-care testing and laboratory use. The RAMP system
consists of a portable fluorescent reader and single-use disposable test
cartridges, and has the potential to be adapted to more than 250 medical and
non-medical tests currently performed in laboratories. RAMP clinical tests are
commercially available for the early detection of heart attack and congestive
heart failure.
    In late 2006, the Company announced a strategic alliance with 3M Company
to commercialize rapid infectious disease tests. Clinical trials for Staph A
and Flu A/B Tests are now underway, with commercialization expected in 2007.
    In the non-clinical market, RAMP Tests are currently provided for the
environmental detection of West Nile Virus, and biodefense applications
including the rapid on-site detection of anthrax, smallpox, ricin and
botulinum toxin. Several other product applications are under development. The
Company has achieved CE Marking and its Quality Management System is
registered to ISO 13485: 2003 and ISO 9001: 2000.
    Response Biomedical is a publicly traded company, listed on the TSX
Venture Exchange under the trading symbol "RBM" and quoted on the OTC Bulletin
Board under the symbol "RPBIF". For further information, please visit the
Company's website at www.responsebio.com.

    The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.

    Statements contained in this press release relating to future results,
events or developments, for example, statements containing the words
"believes," "may," "could", "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects", "goal" and similar expressions, are
"forward-looking statements" or "forward-looking information" under applicable
United States and Canadian securities laws. Forward-looking statements or
information may involve, but are not limited to, comments with respect to our
planned activities, business plan and strategies and their future
implementation, and our expectations for our financial condition and the
results of, or outlook for, our business operations generally. Forward-looking
statements or information are subject to the related assumptions made by us
and involve known and unknown risks, uncertainties and other factors that may
cause actual results, events or developments to be materially different from
those expressed or implied by such statements or information.
    Many of such risks, uncertainties and other factors form part of our
underlying assumptions, and include, among other things, technological changes
that impact our existing products or our ability to develop and commercialize
our products; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; our ability
to obtain and maintain rights to technology from licensors; liability for
patent, product liability and other claims asserted against us;
commercialization limitations imposed by patents owned or controlled by third
parties; technical risk in research and development; adverse results or
unexpected delays in product development and clinical trials; our ability to
effectively and efficiently manage the planned growth of our operations; our
ability to obtain, and the timing of, necessary regulatory approvals;
competition including competition from others with significantly more
resources; market acceptance of our products and the size of our markets;
changes in business strategy or development plans; general economic and
business conditions where we operate; and other factors referenced in our
annual report on Form 20-F and other filings with Canadian and United States
securities regulatory authorities.
    Given these uncertainties, assumptions and risks, readers are cautioned
not to place undue reliance on such forward-looking statements or information.
We disclaim any obligation to update, or to publicly announce any revisions
to, any such statements or information to reflect future results, events or
developments.





For further information:

For further information: Response Biomedical Contacts: Bill Wickson,
Manager, Investor Relations, Response Biomedical Corporation, Tel (604)
456-6073, Email: bwickson@responsebio.com; Brian Korb, Vice President, The
Trout Group LLC, Tel: (646) 378-2923, Email: bkorb@troutgroup.com

Organization Profile

RESPONSE BIOMEDICAL CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890